February, 2-4, 2027 | Washington D.C.

www.nasal-formulation-delivery.com

REGISTER BY FRIDAY, DECEMBER 11 & SAVE UP TO $600

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



5th Annual

Nasal Formulation & Delivery Summit

Optimize Safe & Efficient Drug Delivery, Achieve Clinical Success, Futureproof Commercial Strategy

Navigate Drug-Device Compatibility, Predictive Clinical Translation, CMC, Regulatory Pathways for Combination Products, & Investment Strategy to Advance Best in Class Intranasal Delivery

Expert Speakers Include:



Stuart Madden
Chief Scientific Officer
Neurelis



Heather Loring
Associate Director, Search & Evaluation
AstraZeneca



Robert Rönn
Senior VP Head of Research & Development
Orexo



Paul Radspinner
President & Chief Executive Officer
FluGen



Tracy Brandmeyer
Chief Executive Officer & Co-Founder
Cognigenics



Timothy Sullivan
Chief Executive Officer
Zeteo Biomedical

Proud to Partner With:

intertek Total Quality. Assured. | Kindeva | Aptar pharma | Lipoid We Invest in Quality. | SILGAN DISPENSING

+1 617 455 4188 info@hansonwade.com

www.nasal-formulation-delivery.com

hansonwade

Welcome to the 5th Nasal Formulation & Delivery Summit

5th Annual Nasal Formulation & Delivery Summit
February, 2-4, 2027 | Washington D.C.

Intranasal delivery is at a tipping point. The first approved nose-to-brain therapy has validated the approach, while easier administration, delivery efficiency, and lifecycle management opportunities are driving investment across multiple therapeutic areas. With a growing wave of innovative biotechs reporting promising clinical results and the industry anticipating its next landmark approval, intranasal drug delivery has never offered greater opportunity or excitement.

The **5th Nasal Formulation & Delivery Summit** is uniting leading biotechs, pharma, and investors to optimize drug and device compatibility, overcome challenges in formulation, and navigate commercial strategy and investment to optimize efficient drug delivery.

From optimizing nose-to-brain delivery and improving bioavailability, to navigating challenging funding opportunities, join **70+ CEOs**, **CSOs**, and **Heads of R&D**, **Formulation** and **CMC** to advance intranasal treatments for CNS, neurological, infectious, and emergency-use indications, delivering unparalleled patient efficacy.

What past attendees have to say

"As someone relatively new to the intranasal drug delivery field, I found the 4th Nasal Drug Delivery Symposium extremely valuable and enjoyable. The meeting provided an excellent balance of scientific depth, practical development insights, and opportunities…"

EmerRx Biopharma

"I liked the intimate nature of the conference. The quality of the speakers and talks was also strong!"

Synap Biotech

Key Benefits of Attending



Understand the evidence, imaging approaches, preclinical models, and regulatory strategies required to support CNS-targeted intranasal therapies with insights from **Neurelis**, **Vistagen**, **Noveome Biotherapeutics**, and **Oragenics**.



Discover how leaders are addressing the disconnect between promising preclinical data and successful human outcomes through better models, biomarkers, and translational strategies with **Olfera**, **Nasus Pharma**, and leading intranasal drug developers.



Evaluate how leading innovators including **Orexo**, **Marinomed Biotechnologie**, **Lion.bio**, **Affilogic**, **Logix Biosciences**, and **FluGen** are leveraging powders, peptides, biologics, nanocarriers, and novel intranasal platforms to improve product performance and expand therapeutic opportunities.



Learn how companies are integrating formulation, device selection, human factors, and manufacturing considerations earlier to reduce development risk with **Zeteo Biomedical**, **Belhaven Biopharma**, and **Orexo**.



Network with C-Suites and Heads from **Neurelis**, **Vistagen**, **Orexo**, **Therakind**, **FluGen**, **Tiziana Life Sciences**, **Marinomed Biotechnologie**, **Zeteo Biomedical**, and more at the only industry forum dedicated to developing and commercializing intranasal therapies.

+1 617 455 4188 info@hansonwade.com
www.nasal-formulation-delivery.com
hansonwade

What's New For 2027?

5th Annual Nasal Formulation & Delivery Summit
February, 2-4, 2027 | Washington D.C.

Key Sessions Not to Miss

Exploring Novel Intranasal Approaches to Build Confidence in CNS Delivery & Clinical Success

1. Exploring Novel Intranasal Approaches to Build Confidence in CNS Delivery & Clinical Success with **Therakind**, **Noveome**, **Vistagen**, and **Oragenics**
2. Leveraging Target Site Delivery to Unlock New Therapeutic Opportunities Beyond Traditional Nasal Sprays with **Olfax**, **Flugen**, and **VCU**
3. Integrating Drug, Device & Development Strategy to Reduce Risk & Accelerate Commercial Success with **Zeteo** and **Belhaven Biopharma**
4. Exploring Predictive Models & Preclinical Strategies to Accelerate Clinical Translation with **Olfera** and **Nasus Pharma**
5. Optimizing Formulation & Bioavailability to Improve Intranasal Product Performance with **Orexo** and **Lionbio**

Disease & Application Representation

- **CNS & Neurological Disorders**
- **Infectious Disease & Vaccines**
- **Emergency-Use Therapies**
- **Next-Generation Biologics, Peptides & RNA Therapies**
- **Immune Modulation & Inflammation**

New Companies for 2027

ZETEO BIOMEDICAL · Belhaven BIOPHARMA · FluGen · LB · OlfaxMedica · Cognigenics · ORAGENICS · orexo

New This Year...

- **Brand new interactive session** where you get to solve your biggest industry challenges with your peers!
- **New content** exploring powders, biologics, peptides, vaccines, and advanced modalities
- **Greater emphasis** on regulatory expectations and FDA alignment
- **More discussion** around commercial success, development risk reduction, and investor confidence
- **New location** in Washington DC to improve accessibility for attendees and speakers

+1 617 455 4188 info@hansonwade.com
www.nasal-formulation-delivery.com

hansonwade

Your Expert Speakers



Heather Loring
Associate Director, Search & Evaluation
AstraZeneca
New Big Pharma



Olivier Kitten
Founder & Chief Executive Officer
Affilogic



Brian Taubenheim
Chief Operations Officer
Belhaven Biopharma



Tracy Brandmeyer
Chief Executive Officer & Co-Founder
Cognigenics



Paul Radspinner
President & Chief Executive Officer
Flugen



Robin Guo
Chief Executive Officer
Lionbio



Gavin Gear
Chief Executive Officer & Owner
Logix Biosciences



Sefi Rosenfeld
Director of Preclinical & Early Development
Nasus Pharma



Stuart Madden
Chief Scientific Officer
Neurelis



Larry Brown
Chief Scientific Officer
Noveome Biotherapeutics



Jason Cook
Co-founder & Chief Medical Officer
Olfax Medical



James Kelly
Chief Medical Officer
Oragenics



Robert Rönn
Senior VP Head of Research & Development
Orexo



Susan Conroy
Chief Executive Officer
Therakind



Stephen Shrewsbury
Fractional Chief Medical Officer
TransformaBio & Lionbio



Zachary Warnken
Director, Pharmaceutical Development
Via Therapeutics LLC



Angel Angelov
Chief Medical Officer
Vistagen



Timothy Sullivan
Chief Executive Officer
Zeteo Biomedical

Proud Partners:



Mark Parry
Senior Scientific Director
Intertek

> "A mixing of people from Pharma, devices and new companies developing new products with nasal inhalers!"
>
> **CSS Pharma**

Pre-Conference Workshop Day
Tuesday, February 2

Registration & Morning Coffee — 8.00

Workshop A — 9:00

Navigating Regulatory Expectations for Intranasal Products, Nose-to-Brain Therapies, & Novel Delivery Platforms

This interactive workshop brings together industry experts to explore evolving FDA and global regulatory expectations, providing practical guidance on building development programs that reduce regulatory risk and accelerate progress toward the clinic.

Discussion Areas:

- What evidence do regulators actually require to support nose-to-brain claims?
- Understanding FDA expectations for powders, biologics, and novel delivery technologies
- Bioequivalence vs in vitro bioequivalence pathways
- Addressing regulatory uncertainty surrounding direct CNS delivery
- Bridging conflicting expectations around animal testing, modeling, and safety packages
- Learning from successful INDs, NDAs, and regulatory interactions
- Understanding the value of systemic exposure for nose to brain delivery
- Reducing regulatory risk by aligning device reliability, human factors, and manufacturing strategy early in nasal combination product development

Workshop Leaders



Stuart Madden
Chief Scientific Officer
Neurelis



Stephen Shrewsbury
Fractional Chief Medical Officer
Lionbio & TransformBio



Brian Taubenheim
Chief Operations Officer
Belhaven Biopharma

Lunch — 12:00

Workshop B — 13:00

From Nose-to-Brain Theory to Clinical Success: Building a Development Strategy That Investors, Regulators, & Partners Will Support

This highly practical workshop is designed for teams looking to understand what separates successful intranasal development programs from those that fail. Through open discussion, attendees will explore how to build robust development strategies that generate confidence among investors, partners, regulators, and future commercial stakeholders.

Discussion Areas:

- What evidence convinces investors to fund intranasal programs to de-risk programs?
- Understanding reimbursement and commercialization requirements and avoiding common development
- Understand how large pharma evaluates emerging intranasal technologies, platforms, and therapeutic programs when considering partnership or licensing opportunities
- Identify the scientific, clinical, and regulatory milestones that increase confidence and help transform promising innovation into a commercially attractive asset
- Learn how developers can reduce perceived development risk, strengthen differentiation, and build evidence packages that support productive conversations with strategic partners

Workshop Leaders



Jason Cook
Co-founder & Chief Executive Officer
Olfax



Heather Loring
Associate Director, Search & Evaluation
AstraZeneca

End of Workshop Day — 16:00

Conference Day One
Wednesday, February 3

7:30 **Morning Coffee & Check-In**



Stuart Madden
Chief Scientific Officer
Neurelis

8:20 **Chair's Opening Remarks**

Exploring Novel Intranasal Approaches to Build Confidence in CNS, Nose-to-Brain Delivery, & Clinical Success



Susan Conroy
Chief Executive Officer
Therakind

8:30 **The Evolution of Intranasal Drug Delivery: Lessons Learned from Developing the Next Generation of Nasal Products**

- Explore how intranasal drug delivery has evolved over the last decade, examining the scientific, regulatory, commercial, and technological developments that are shaping the next generation of nasal therapies
- Understand the critical decisions developers must make when selecting formulations, delivery devices, and development strategies, ensuring both the therapeutic and delivery system are optimized for long-term clinical and commercial success
- Learn lessons from progressing intranasal products through development and regulatory review, identifying common development challenges, unexpected barriers, and opportunities that continue to drive innovation across the nasal delivery landscape



Angel Angelov
Chief Medical Officer
Vistagen

9:00 **Exploring if Intranasal Therapies Deliver Clinical Benefit Without Direct Systemic Exposure**

- Explore alternative mechanisms through which intranasal therapies may influence CNS pathways and clinical outcomes
- Understand how clinical and translational evidence can support novel nasal mechanisms without relying solely on traditional pharmacokinetic approaches
- Examine lessons learned from developing intranasal therapies targeting neurological and psychiatric disorders



James Kelly
Chief Medical Officer
Oragenics
CNS & Neurological Disorder

9:30 **Advancing a First-in-Class Intranasal Neurosteroid for Concussion: Lessons from Clinical Development of a Direct-to-Brain Therapy**

- Understand the scientific rationale for targeting concussion and traumatic brain injury through intranasal direct-to-brain delivery
- Explore the challenges of generating translational, safety, and clinical evidence to support progression of a novel neurological therapy into human studies
- Learn lessons from advancing a clinical-stage intranasal program, including regulatory strategy, development planning, and building confidence in direct CNS delivery

10:00 **Morning Break & Speed Networking**
The ideal opportunity to get face-to-face with many global nasal formulation and delivery leaders for important in-depth conversations.



Tracy Brandmeyer
Chief Executive Officer
& Co-Founder
Cognigenics

11:00 **Leveraging Intranasal RNA Therapeutics to Target CNS Circuits Beyond the Blood-Brain Barrier**

- Explore how intranasal RNA therapies can enable targeted modulation of neural circuits while avoiding systemic exposure
- Understand the opportunities and challenges of delivering RNA therapeutics directly to the brain through nose-to-brain pathways
- Learn how next-generation genetic medicines may unlock new treatment approaches for cognitive, psychiatric, and neurodegenerative disorders

Conference Day One
Wednesday, February 3

Leveraging Target Site Delivery to Unlock New Therapeutic Opportunities Beyond Traditional Nasal Sprays

Kindeva

11:30 **Session Reserved for Kindeva**



Larry Brown
Chief Scientific Officer
Noveome Biotherapeutics
CNS & Nose-to-Brain

12:00 **Unlocking the Potential of Nose-to-Brain Biologic Delivery for Neuroprotection in CNS Disorders**

- Exploring how intranasal delivery can bypass the blood-brain barrier to enable direct access to the central nervous system
- Examining the opportunities and challenges of developing potent biologics for neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS
- Understanding the scientific, clinical, and commercial considerations needed to drive broader adoption of nose-to-brain therapeutics

12:30 **Lunch Break**



Jason Cook
Co-founder & Chief Executive Officer
Olfax
CNS & Neurological Disorder

1.30 **Delivering Beyond the Olfactory Region: Understanding Multiple Pathways to the CNS**

- Explore how targeted intranasal access to the sphenopalatine ganglion may offer an alternative approach to influencing CNS-relevant pathways beyond traditional olfactory-focused delivery strategies
- Understand the development journey from clinician-administered SPG procedures to scalable intranasal drug-device combination products capable of improving patient access and treatment convenience
- Learn how delivery strategy, formulation design, and device development must work together to support successful clinical translation, regulatory development, and future commercialization opportunities



Mark Parry
Senior Scientific Director
Intertek

2:00 **Ondansetron Nasal Delivery: Translating Formulation Properties into Device Performance**

- Initial screening of Ondansetron formulations for nasal delivery
- Evaluation of nose-to-brain (N2B) and conventional nasal delivery devices
- Early formulation–device performance insights and key considerations for further development



Paul Radspinner
President & Chief Executive Officer
Flugen
Infectious Disease & Vaccines

2:30 **Harnessing the Nasal Mucosa to Drive Protective Immune Responses: Advancing the Next Generation of Intranasal Vaccines**

- Explore how targeting the nasal mucosa can generate differentiated immune protection by stimulating local mucosal immunity and cellular immune responses at the site of pathogen entry as well as in serum, providing a distinct immunological profile compared to traditional systemic antibody responses achieved through injectable vaccines
- Understand the historical biases as well as scientific and development challenges associated with intranasal vaccine platforms, including achieving durable immune protection, demonstrating clinical efficacy, optimizing deposition within the nasal cavity, and building confidence in alternative immune correlates of protection
- Learn how next-generation intranasal vaccines are leveraging favorable safety profiles, needle-free administration, and mucosal and serum immune activation to improve patient acceptance, expand access, and create new opportunities for preventing infectious respiratory diseases beyond traditional vaccination approaches

Conference Day One
Wednesday, February 3

Integrating Drug, Device, & Development Strategy to Reduce Risk & Accelerate Commercial Success



Timothy Sullivan
Chief Executive Officer
Zateo

3:00 Integrating Formulation, Device, & Combination Product Strategy Early to Avoid Costly Late-Stage Development Changes

- Avoid costly reformulation, redevelopment, and regulatory delays by integrating formulation, device, and combination-product strategy from the earliest stages of development rather than treating them as separate workstreams
- Understand how formulation characteristics, delivery route requirements, and device performance interact to influence product success, patient usability, manufacturability, and long-term commercial viability
- Learn practical lessons from developing integrated liquid and powder-based intranasal products, highlighting common mistakes that lead to drug-device compatibility challenges and how to prevent them



3:30 Afternoon Break & Poster Session
Witness some of the latest and greatest research in the nasal drug development & delivery field by drug developers, academics, service providers, and researchers in this spotlight poster session!



Brian Taubenheim
Chief Operations Officer
Belhaven Biopharma
Emergency-Use Therapies

4:30 Building Development-Ready Nasal Combination Products: Lessons Learned from Advancing a Powder-Based Emergency Therapy

- Understand how early integration of formulation development with device design and manufacturing capacities while meeting regulatory requirements can prevent costly late-stage redesigns, delays, and regulatory setbacks
- Explore the key development challenges associated with advancing powder-based combination products, including device reliability requirements, human factors trials, clinical development planning, and regulatory expectations
- Learn how teams can build commercially viable intranasal products by integrating patient, payer, and provider perspectives into target product profiles

5:00 Panel Discussion: Has the Industry Finally Solved Nose-to-Brain Delivery?

- Identify the critical scientific, translational, and clinical evidence gaps that remain before nose-to-brain delivery can achieve widespread regulatory acceptance and commercial adoption
- Understand what regulators still need to see regarding reproducibility, biodistribution, imaging, clinical outcomes, and direct CNS exposure before confidently supporting nose-to-brain claims
- Debate whether current preclinical models, analytical tools, imaging technologies, and translational approaches are sufficient to predict human outcomes and support development decisions
- Separate genuine scientific progress from industry hype by examining which technologies, pathways, and approaches are producing meaningful evidence versus those that continue to face significant validation challenges



James Kelly
Chief Medical Officer
Oragenics



Stuart Madden
Chief Scientific Officer
Neurelis



Angel Angelov
Chief Medical Officer
Vistagen



Larry Brown
Chief Scientific Officer
Noveome Biotherapeutics



Stuart Madden
Chief Scientific Officer
Neurelis

5:30 Chair's Closing Remarks

5:35 End of Conference Day 1

Conference Day Two
Thursday, February 4

8:00 Morning Coffee & Check-In

8:50 Chair's Opening Remarks

Translating Intranasal Products into Clinically & Commercially Viable Therapies

9:00 **Advancing Powder-Based Nasal Products: Leveraging Stability & Rapid Absorption to Unlock Next-Generation Intranasal Therapies**



Robert Rönn
Senior Vice President & Head, Research & Development
Orexo
Powder Formulation

- Explore how powder formulations can overcome stability limitations associated with traditional liquid products while simplifying storage, transportation, and long-term product performance
- Understand how formulation and device design influence deposition, absorption, and pharmacodynamic performance, including lessons learned from clinical development
- Learn how developers are overcoming regulatory, manufacturing, and product-development challenges when advancing powder-based intranasal products toward commercialization

9:30 **Expanding the Therapeutic Potential of Intranasal Delivery: From Immune Modulation to Next-Generation Anti-Infectives**



Gavin Gear
Chief Executive Officer & Owner
Logix Biosciences
Infectious Disease

- Explore how intranasal delivery is creating new opportunities for immune modulation, infectious disease prevention, and treatment beyond traditional symptomatic therapies
- Understand how local nasal delivery can improve therapeutic effectiveness while reducing systemic exposure and minimizing development challenges associated with conventional administration routes
- Evaluate emerging strategies being used to address antimicrobial resistance and respiratory health through innovative intranasal therapeutic platforms

10:00 Morning Break & Networking

Selecting the Right Formulation Strategy & Improving Bioavailability to Maximize Product Performance & Development Success

11:00 **Selecting the Right Formulation Strategy For Intranasal Therapies: Balancing Performance, Risk & Manufacturability**



Zachary Warnken
Director, Pharmaceutical Development
Via Therapeutics LLC

- Develop a framework for selecting the most appropriate formulation approach based on molecule characteristics, target indication, and delivery objectives
- Understand the trade-offs between powders, liquids, nanoparticles, and enhanced formulations when balancing efficacy, manufacturability, stability, and patient experience
- Avoid costly reformulation and development delays by aligning formulation strategy with long-term clinical, regulatory, and commercial goals

11:30 **Pioneering Intranasal Delivery of Novel Biologics to Unlock New Therapeutic Opportunities**



Olivier Kitten
Founder & Chief Executive Officer
Affilogic
Infectious Disease

- Explore how next-generation biologic modalities can overcome traditional delivery barriers to enable effective intranasal administration while maintaining therapeutic activity
- Understand how intranasal biologics can leverage local mucosal immunity to provide differentiated therapeutic benefits across infectious disease and other emerging applications
- Learn from the development of novel biologic platforms and the scientific, translational, and regulatory considerations required to progress these therapies toward clinical success

Conference Day Two
Thursday, February 4



Robin Guo
Chief Executive Officer
Lionbio

12:00 **Improving Bioavailability Through Smarter Formulation Design: Enhancing Performance Without Increasing Development Complexity**

- Explore how nanoparticle-enabled delivery systems can overcome absorption barriers associated with peptides and biologics while minimizing systemic exposure
- Understand how intranasal GLP-1 delivery may create differentiated therapeutic profiles by targeting CNS pathways while potentially reducing gastrointestinal side effects
- Learn how developers are balancing bioavailability, manufacturability, safety, and scalability when advancing next-generation peptide therapies

12:30 **Lunch Break**

Exploring Advanced Models & Preclinical Strategies to Accelerate Clinical Translation



Sefi Rosenfeld
Director, Pre-Clinical & Early Clinical Development
Nasus Pharma
Powder Formulation

1:30 **Generating Meaningful Preclinical Data for Powder-Based Intranasal Products: Opportunities, Challenges, & Lessons Learned**

- Explore the unique challenges associated with evaluating powder-based intranasal products in preclinical studies, including administration techniques, dose accuracy, and reproducibility across animal models
- Understand the strengths and limitations of commonly used preclinical approaches for assessing safety, pharmacokinetics, deposition, and product performance when developing nasal powders
- Review practical strategies developers are using to generate more relevant preclinical data and improve confidence when progressing powder-based products toward clinical development

2:00 **Collaborative Discussion: Nasal Insights Exchange**

Brand New Interactive Session

Where the Industry Solves Its Biggest Nasal Challenges Together

At the start of the session, attendees will be invited to submit the single biggest obstacle they are currently facing via a live poll. Whether it's demonstrating nose-to-brain delivery, improving clinical translation, overcoming bioavailability limitations, selecting the right device strategy, navigating regulatory uncertainty, or progressing next-generation biologics, every challenge is welcome.

We'll consolidate the responses into the most common themes and divide attendees into facilitated discussion groups to explore practical solutions together.

Each group will work through three key questions:

- What is the root cause of this challenge and why does it continue to persist across the industry?
- What approaches have been attempted so far, and why have they succeeded or failed?
- What is the single highest-impact action the industry could take to overcome this challenge?

Facilitated by the Chair.

3:00 **Chair's Closing Remarks**

3.05 **End of Conference**

2027 Partners

Expertise Partner

With more than 35 years of experience in orally inhaled and nasal drug products (OINDPs), Intertek Pharmaceutical Services is your trusted partner for the development and regulatory advancement of innovative respiratory and nasal therapies. Our expertise spans analytical and bioanalytical testing, formulation support, device performance testing, extractables and leachables, and GMP-compliant testing and manufacturing services. With a strong focus on nasal drug delivery, including nose-to-brain (N2B) approaches and CNS-targeted therapies, we help clients overcome complex development challenges, generate robust data packages, and accelerate products from early development through commercialization and global regulatory approval.

www.kindevadd.com

Expertise Partner

At Kindeva, our purpose is clear: manufacturing more tomorrows for patients worldwide. By investing in the highest quality facilities, finished-dose CDMO solutions and analytical capabilities, we provide strategic value that extends beyond manufacturing. Our global network of 10 manufacturing and R&D facilities offers exceptional capabilities, including expanded aseptic fill finish capacity and next-generation green propellant technologies. We leverage our sterile injectable, pulmonary, nasal, and dermal expertise to help meet the demands of today and deliver the possibilities of tomorrow.

www.kindevadd.com

Exhibition Partner

Aptar Pharma is an expert in nasal drug delivery, offering advanced intranasal systems and drug delivery services from design and manufacture, formulation development and clinical product manufacturing to post launch support. Our global network of GMP manufacturing sites help us accelerate and derisk drug product development, and our investments in R&D and innovation allow us to offer proven nasal drug delivery solutions to help improve patient outcomes across the globe.

www.aptar.com

Exhibition Partner

Since its foundation in 1977, Lipoid has gained an outstanding reputation in the development and industrial production of high-quality lecithin, phospholipids, and other lipid products, meeting the high standards of the pharmaceutical industry. Lipoid is the world's leading company for the production and supply of a wide range of natural and synthetic phospholipid excipients on an industrial scale. Our production processes have been optimized over many years to ensure a sustainable supply from renewable sources under highest environmental standards.

www.lipoid.com

Get Involved



Karim Hoceine
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

2027 Partners

Exhibition Partner

In healthcare, dispensing goes beyond delivering medication - it's about protecting formulations and ensuring patients receive accurate, reliable dosing. Silgan Dispensing combines advanced engineering with user-focused design to create customized solutions tailored to each product and patient. Backed by strong R&D and global investment, we support healthcare brands with high-quality dispensing technologies across nasal, ophthalmic, and dermal applications - helping improve outcomes while delivering a safe, consistent, and comfortable patient experience.

www.silgan.com

> "Lorem ipsum dolor sit amet, con sect etur adipiscing elit. Donec nec ipsum sit amet purus. Lorem ipsum dolor sit purus. Donec nec ipsum sit amet purus. Lorem ipsum"
>
> **Lorem ipsum**

> "Lorem ipsum dolor sit amet, con sect etur adipiscing elit. Donec nec ipsum sit amet purus. Lorem ipsum dolor sit purus. Donec nec ipsum sit amet purus. Lorem ipsum"
>
> **Lorem ipsum**

Get Involved



Karim Hoceine
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

5th Annual Nasal Formulation & Delivery Summit
February, 2-4, 2027 | Washington D.C.

Your Platform to Engage the Fastest Growing Community in Intranasal Drug Delivery

Intranasal drug delivery is entering a pivotal phase of growth, driven by recent approvals, expanding clinical pipelines, and increasing interest in CNS, emergency-use, vaccine, and biologic applications. As developers work to improve clinical translation, demonstrate confidence in nose-to-brain delivery, and advance therapies toward commercialization, the need for robust formulation, device, regulatory, and manufacturing strategies has never been greater. Now more than ever, companies are seeking innovative partners with expertise in formulation development, device technologies, analytical testing, translational models, manufacturing, and regulatory strategy to accelerate the next generation of intranasal therapies.

Meet the Companies Shaping the Future of Intranasal Delivery
Connect with CEOs, CSOs, Heads of R&D, Formulation, CMC, Clinical Development, and Product Development actively advancing nasal therapies.

Position Your Organization Alongside Industry Leaders
Demonstrate your expertise to a highly targeted audience seeking solutions to formulation, device, manufacturing, translational, and regulatory challenges.


Generate Commercial Opportunities
Engage decision-makers actively evaluating CDMOs, device developers, formulation providers, and development partners.

Seniority of Attendees



- CXO (CEO, CSO) 46%
- VP / Head 12%
- Director 9%
- Scientist / Team Lead 21%
- Manager 6%
- Other 6%

Type of Companies Attending



- Drug Developers
- Academic & Research Institutes
- Service Providers & Others

*Statistics Taken from 4th Nasal Formulation & Delivery Summit

Get Involved



Karim Hoceine
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.nasal-formulation-delivery.com

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER
How industry leaders are overcoming translational, regulatory, and clinical barriers to advance next-generation intranasal therapies.

BUILD
Your understanding of nose-to-brain delivery, target site deposition, formulation strategy, bioavailability, and drug-device integration.

ENGAGE
With 70+ CEOs, CSOs, Heads of R&D, Formulation, Clinical Development, and CMC to build relationships, foster collaboration, and accelerate your programs.

Drug Developers	Register by Friday, December 11 & Save up to $600	On the Door Price
Conference + 2 Workshops	$3,907	$4,507
Conference + 1 Workshop	$3,378	$3,828
Conference Only	$2,849	$3,149
Academic & Research Institutes**	Register by Friday, December 11 & Save up to $600	On the Door Price
Conference + 2 Workshops	$3,307	$3,907
Conference + 1 Workshop	$2,878	$3,328
Conference Only	$2,449	$2,749
Solution & Service Providers	Register by Friday, December 11 & Save up to $300	On the Door Price
Conference + 2 Workshops	$5,097	$5,397
Conference + 1 Workshop	$4,398	$4,698
Conference Only	$3,699	$3,999

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website forfull pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

The Westin Washington Dulles Airport
2520 Wasser Terrace, Herndon, VA 20171

For further information or assistance, please visit: https://www.marriott.com/en-us/hotels/iadwi-the-westin-washington-dulles-airport/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom